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Mo-CBP3 is an antifungal protein produced by Moringa oleifera which has been investigated as potential
candidate for developing transgenic crops. Before the use of novel proteins, food safety tests must be
conducted. This work represents an early food safety assessment of Mo-CBP3, using the two-tiered
approach proposed by ILSI. The history of safe use, mode of action and results for amino acid
sequence homology using the full-length and short contiguous amino acids sequences indicate low risk
associated to this protein. Mo-CBP3 isoforms presented a reasonable number of alignments (>35%
identity) with allergens in a window of 80 amino acids. This protein was resistant to pepsin degradation
up to 2 h, but it was susceptible to digestion using pancreatin. Many positive attributes were presented
for Mo-CBP3. However, this protein showed high sequence homology with allergens and resistance to
pepsin digestion that indicates that further hypothesis-based testing on its potential allergenicity must
be done. Additionally, animal toxicity evaluations (e.g. acute and repeated dose oral exposure assays)
must be performed to meet the mandatory requirements of several regulatory agencies. Finally, the
approach adopted here exempliﬁed the importance of performing an early risk assessment of candidate
proteins for use in plant transformation programs.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Fungi are responsible for several diseases that attack plants
causing damages in various important crops, decreasing their
productivity (Mandal et al., 2013; Labandeira and Prevec, 2014).
Furthermore, the chemical control used as strategy in combating
fungal diseases is associated with toxic and hazardous effects on
the environment and nontarget organisms (Meng et al., 2010;
Marei et al., 2012; Yadav et al., 2013). Modern strategies to
confront this problem include conventional plant breeding, which
is conceptually supported by crossing of plants with desired char-
acteristics, and genetic engineering, which aims to obtain trans-
genic plants expressing deﬁned characteristics (Qaim, 2010; Zhang
et al., 2010; Wang et al., 2014)..F. Farias), imvasco@ufc.brSigniﬁcant efforts have been directed towards the identiﬁcation
of antifungal proteins that can be used for producing crops resistant
to pathogens. Despite the importance of this issue, no commercial
transgenic plant is available with genes that encode proteins to
confer resistance against phytopathogenic fungi. On the other
hand, several studies have already described the efﬁcacy of anti-
fungal proteins when processed on different host plants, either in
laboratory or greenhouse conditions (Lacerda et al., 2014).
Moringa oleifera Lamarck is a native plant from northwest In-
dia, with distribution in various parts of the world, mainly in the
tropics. M. oleifera is known as a multipurpose tree since it has
been widely used as food and feed, as well as in the traditional
medicine and industry (Ramachandran et al., 1980; Anwar et al.,
2007; Ben Salem and Makkar, 2009; Kumar et al., 2010). From
the seeds of this plant species, a chitin-binding protein, Mo-CBP3
(M. oleifera e Chitin-Binding Protein), has been puriﬁed. Mo-CBP3
possesses a broad spectrum of activity against important phyto-
pathogenic fungi, such as Fusarium oxysporum, Fusarium solani,
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musae (Gifoni et al., 2012). As to its structural attributes, Mo-CBP3
is a glycoprotein with apparent molecular mass of 18.0 kDa, pre-
senting multiple heterodimeric isoforms composed of two
different polypeptide chains linked by disulﬁde bonds. It is a
highly stable protein, maintaining its secondary structure and
antifungal activity at extremes of temperature and pH (Batista
et al., 2014). In this context, Mo-CBP3 protein may represent a
promising tool for use in the development of transgenic crops
resistant to phytopathogenic fungi. Indeed, the Embrapa (Brazilian
Agricultural Research Corporation) group has considered the in-
clusion of this protein in its plant transformation programs.
However, this company in a partnership with our team has agreed
to perform early food safety assessments of candidate proteins
before their introduction into crops. This could avoid the use of
inappropriate protein for costly activities involved in the pro-
duction of transgenic plants as well as may help to guide modi-
ﬁcations in the protein structure in order to free it of its potential
risks. Current strategies for food safety assessment of candidate
proteins are essentially based on the guidelines of FAO and WHO
compiled in the second edition of the Codex Alimentarius docu-
ment (Codex Alimentarius, 2009).
The International Life Sciences Institute (ILSI) proposed a well-
accepted alternative guideline (Delaney et al., 2008). It is a two-
tiered evaluation, based on weight of evidence, to assess the
safety of novel proteins. The steps consist of potential hazard
identiﬁcation of the protein (Tier I) and hazard characterization
(Tier II), performed when the results of the ﬁrst stage are not
sufﬁcient to deﬁne safety. Tier I includes an assessment of the
biological function or mode of action and intended application of
the protein, history of safe use, comparison of the amino acid
sequence of the protein to other proteins, biochemical and phys-
icochemical properties, as well as the expression level and dietary
intake of the recombinant proteins. Tier II comprises acute and
repeated dose toxicological studies and/or hypothesis-based
testing. In fact, the ILSI guideline is a more ﬂexible approach
because it takes into account all data obtained in a holistic way.
The predictive value of each piece of evidence should be well
understood in order to give some data more ‘weight’ than others
during the assessment, adding greater conﬁdence in overall
evaluation (Delaney et al., 2008).
Although the two-tiered approach, based onweight of evidence,
proposed by ILSI has been initially planned for proteins in a stage of
the development of the transgenic crop where the protein
expression levels can be estimated, we also believe on their suit-
ability for the safety assessment of new proteins whose use in plant
transformation is still being analyzed. Thus, the present study
aimed to perform an early food safety assessment of the antifungal
protein Mo-CBP3 in an agricultural biotechnology perspective,
following this approach. This study allowed us to gather informa-
tion about the Mo-CBP3 risks that were crucial to formulate de-
cisions on the immediate use of this protein for plant
transformation.
2. Material and methods
2.1. M. oleifera seeds
To obtain the protein of interest,Mo-CBP3,M. oleifera pods were
collected from trees in the Pici Campus at the Federal University of
Ceara (Fortaleza, Brazil). A voucher specimen was deposited in the
Prisco Bezerra Herbarium (Fortaleza, Brazil), at this same Institu-
tion, under number EAC34591. The seeds were then separated from
the pods and kept in plastic containers at room temperature until
the moment of analysis.2.2. Mo-CBP3 preparation
Mo-CBP3 was puriﬁed from crude extract of M. oleifera mature
seeds as well described previously by Gifoni et al. (2012). Brieﬂy,
the crude extract was extensively dialyzed against Milli-Q grade
water and (NH4)2SO4 added to the soluble material, denoted as the
albumins, to yield 90% saturation. Albumin fraction was dissolved
in and dialyzed against the extracting buffer and applied to a chitin
column that had been equilibrated with the same buffer. After
elution with the starting buffer of the unbound proteins from the
column, the chitin-bound proteins, named PNAG and PAC, were
eluted with 0.1 M N-acetyl-D-glucosamine (NAG) that was prepared
in the extracting buffer and with 0.05 M acetic acid (pH 5.0),
respectively. The PNAG samplewas dialyzed against 0.1M acetic acid
and distilled water, lyophilized and applied to a cation-exchange
matrix (Resource S™) that had been previously equilibrated with
0.05 M sodium acetate buffer, pH 5.2. Four major adsorbed protein
peaks (Mo-CBP2,Mo-CBP3,Mo-CBP4, andMo-CBP5) were recovered
after being selectively desorbed by stepwise elution with 0.4, 0.5,
0.6, and 0.7 M NaCl, respectively, included in the equilibrium buffer.
The production of Mo-CBP3 was monitored through quantiﬁca-
tion of soluble proteins by Bradford method (Bradford, 1976), using
a curve constructed with bovine serum albumin as standard. The
puriﬁcation of the protein was monitored by 17.5% SDS-PAGE
(Laemmli, 1970). Brieﬂy, Mo-CBP3 (1 mg/mL) was mixed to 2
sample loading buffer [62.5 mM TriseHCl pH 6.8, 2% SDS, 5% 2-
mercaptoethanol, 10% glycerol and 0.01% bromophenol blue] (1:1,
v/v) and incubated at 100 C for 5 min. Then, 2.5 mg of protein/well
were run at 20 mA/gel for 1 h. Protein bands were visualized by
coomassie brilliant blue R-250 staining.
From the SDS-PAGE proﬁle of Mo-CBP3, the percentage of rela-
tive purity of the protein was calculated using the Image Master 2D
platinum (v.7.0, GE Healthcare) software. This methodology has
been adopted by our team, and it is also widely used by chemical
companies to show the purity of commercialized proteins.
Immediately after the production of theMo-CBP3 and up to 72 h
before its use in the in vitro and in vivo tests, batches of the protein
were checked to verify the maintenance of their bioactivity against
fungi according to themethodologydescribed byGifoni et al. (2012).
2.3. History of safe use of M. oleifera species
A literature review on the history of safe use (HOSU) of
M. oleifera species, source of the Mo-CBP3 protein, was performed
according to the principles described by Constable et al. (2007). For
that search, the PubMed database (http://www.ncbi.nlm.nih.gov/
pubmed/) was accessed, using the following combination of key-
words: (a) “Moringa oleifera” and “food safety”; (b) “Moringa olei-
fera” and “risk assessment”; (c) “Moringa oleifera” and “toxicity”; (d)
“Moringa oleifera” and “nutrition”; (e) “Moringa oleifera” and “re-
view”; and (f) “Moringa oleifera”.
2.4. Amino acid sequence similarity
From cDNA sequences (GenBank accession numbers KF616830
until KF616833) coding for Mo-CBP3 were deduced the amino acid
sequences of four isoforms of this protein referred to asMo-CBP3-1,
Mo-CBP3-2, Mo-CBP3-3, and Mo-CBP3-4 (Freire et al., 2015). These
sequences were used in a FASTA format without the signal peptide
and compared with all protein sequences deposited in seven large
reference public databases: NR, Refseq_Protein, SwissProt, PDB,
Env_nr (http://www.ncbi.nlm.nih.gov/), UniProt SwissProt (http://
www.uniprot.org/) and Uniprot-trEMBL (http://www.expasy.org/).
The algorithm usedwas BLASTP 2.2.29þ and the scoringmatrix was
BLOSUM62. No keyword was used to limit the search. Speciﬁc
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shared identity >50%, the size of the alignment and frequency of
gaps 6%) to determine the signiﬁcance of any similarity found,
since there is no established criterion for search of toxic and/or
antinutritional proteins (Herouet-Guicheney et al., 2009). All
comparisons were run in September 15e29, 2014.
An in silico search was performed to assess sequence similarities
of Mo-CBP3 isoforms with any known allergenic proteins using
criteria established by FAO/WHO (2001). The four sequences were
compared to those of allergens deposited in the following data-
bases: (1) Structural Database of Allergenic Proteins (SDAP) (http://
fermi.utmb.edu/SDAP/), updated in February 2013; (2) Allergen
Database for Food Safety (ADFS) (http://allergen.nihs.go.jsp),
updated in February 2014; (3) AllergenOnline version 14 database
(http://www.allergenonline.com/), updated in January 2014; (4)
Allermatch™ (http://allermatch.org/), updated in August 2012. The
Mo-CBP3 sequences were subjected to FASTA comparisons using as
ﬁlter E-value cutoff of 0.01 for detection of identity >50% for the
full-length sequence similarity, > 35% in a window of 80 amino
acids, and short sequences of eight, seven or six contiguous amino
acids identical to those of known allergenic proteins. To assess the
relevance of immune peptides (8, 7 or 6 amino acids) ofMo-CBP3, a
further search in the epitope (immunogenic determinants) data-
base of the ADFS was conducted. All comparisons were run in
September 15e29, 2014.
2.5. Search of N-glycosylation sites
The full-length acid sequences of Mo-CBP3 isoforms were
analyzed for the presence of N-glycosylation sites by NetNGlyc 1.0
Server program (http://www.cbs.dtu.dk/services/NetNGlyc/).
2.6. Mode of action and speciﬁcity
A literature review was conducted on the mode of action and
speciﬁcity of Mo-CBP3 following the recommendations of Delaney
et al. (2008). The PubMed database (http://www.ncbi.nlm.nih.
gov/pubmed/) was accessed, using the following combination of
keywords: (1) “mode of action” and “Mo-CBP3”; (2) “mode of ac-
tion” and “Mo-CBP3” and “speciﬁcity”.
2.7. In vitro digestion
Susceptibility to in vitro digestion of Mo-CBP3 was assessed by
incubating this protein in simulated gastric ﬂuid (SGF) and simu-
lated intestinal ﬂuid (SIF) (Sigma, USA) at a concentration of 0.5mg/
mL. The SGF is a mixture of 0.034 M NaCl, 0.7% HCl, pH 1.0e2.0, and
3.2 mg/mL of pepsin (Sigma P7012), while SIF is composed of
0.05 M potassium phosphate, pH 7.5 and 10 mg/mL of pancreatin
(Sigma P7545), both prepared according to the recommendations
of Roesler and Rao (2001). The mixture of Mo-CBP3 in SGF or SIF
was incubated at 37 C, under constant agitation, and aliquots of
200 mL removed after 0, 15, 30, 60 s, 2, 5, 10, 20, 30 min, 1 and 2 h.
The tests were run in triplicate in the different ﬂuids. Bovine serum
albumin (BSA) was used as a digestible protein control. The di-
gestibility of the proteins in SGF and SIF was monitored by 17.5%
SDS-PAGE and Western blot analyses using anti-Mo-CBP3 rabbit
polyclonal antibodies (1:10,000).
3. Results
3.1. Mo-CBP3 preparation
The protein yield of Mo-CBP3 preparations used in the present
study was 10.89 ± 1.65 mg protein/g defatted seed ﬂour. Thebatches were homogeneous and free of contaminants as shown by
SDS-PAGE. A single protein band with an apparent molecular mass
of 18.0 kDa, under non-reducing condition, was observed. This
protein when treated with 2-mercaptoethanol migrated as two
protein bands with apparent molecular masses of 4.1 and 8.1 kDa.
To be sure that the protein remained active after all puriﬁcation
steps performed, Mo-CBP3 protein batches were assessed for their
bioactivity against fungi. All protein samples presented activity
against F. solani spores in the expected magnitude. The SDS-PAGE
protein proﬁle and antifungal activity data conﬁrmed the ﬁndings
previously reported by Gifoni et al. (2012). Additionally, the purity
of the produced protein was calculated as >99.9%.
3.2. History of safe use of M. oleifera species
The scientiﬁc literature search using a series of keyword com-
binations on the HOSU of M. oleifera species revealed a large
number of reports for all parts (leaves, seeds, bark, roots, sap, and
ﬂowers) of this widely used medicinal plant and source of food
products. As recently reviewed by Stohs and Hartman (2015), a
considerable number of human and animal as well as in vitro
studies indicate that various preparations of M. oleifera leaves and
other plant parts have demonstrated a very high degree of safety.
On the other hand, some reports on adverse effects of M. oleifera
isolated compounds or preparations have been described in animal
or in vitro studies, such as effects in female reproductive system
(Sethi et al., 1988; Shukla et al., 1988; Prakash et al., 1987), geno-
and cytotoxic activities (Villasenor et al., 1989; Rolim et al., 2011;
Asare et al., 2012; Araújo et al., 2013), hypotensive effects (Faizi
et al., 1994, 1998), source of antinutritional factors (Igwilo et al.,
2013, 2014), hepatic and renal damage (Oyagbemi et al., 2013),
and acidosis (Omabe et al., 2014). In parallel to the scientiﬁc data,
for hundreds of years several parts of M. oleifera have been
consumed by humans and animals in many tropical and subtropical
countries with no reports of toxic effects (Fahey, 2005; Thurber and
Fahey, 2009).
3.3. In silico analysis
In silico analysis of the amino acid sequences of Mo-CBP3 iso-
forms revealed no signiﬁcant similarity with sequences of any
known toxic, antinutritional and/or allergenic protein deposited in
seven general protein databases. Likewise, the comparison of the
full-length sequences of all isoforms of Mo-CBP3 with protein se-
quences deposited in the ADFS, Allermatch™, AllergenOnline and
SDAP allergen databases showed no identity >50% (Table 1). On the
other hand, the Mo-CBP3 isoforms showed a reasonable number of
signiﬁcant alignments (>35% identity) when awindow of 80 amino
acids was applied as search parameter in the same allergen data-
bases (Table 1). Table 2 shows minutely all identiﬁed hits for each
Mo-CBP3 isoform. Many well-known allergens were identiﬁed such
as Sin a 1 from Sinapis alba, Ber e 1 from Bertholletia excelsa, Ric c 1/
3 from Ricinus communis and Cor a 14 from Corylus avellana, and
among the different isoforms the identities detected throughout
the databases accessed varied from 35 until 46.25%. The search for
identity with eight contiguous amino acids revealed no identity of
Mo-CBP3 with any known allergen (Table 1). However, identity of
seven contiguous amino acids with known allergens was found for
two isoforms of Mo-CBP3 (Mo-CBP3-2 and Mo-CBP3-3) in ADFS,
Allermatch™ and SDAP databases. Evidences of identity with short
sequences of six contiguous amino acids were found for the four
isoforms of this protein in ADFS and Allermatch™ database. In the
SDAP database, identity with six contiguous amino acids was found
only for Mo-CBP3-2 and Mo-CBP3-3 isoforms (Table 1). In fact, the
various peptides of six contiguous amino acids account only for six
Table 1
Search of similarity between the full-length amino acid sequence of the four isoforms of Mo-CBP3 and known allergenic proteins in speciﬁc databases.a.
Database Mo-CBP3 isoforms
Mo-CBP3-1 Mo-CBP3-2 Mo-CBP3-3 Mo-CBP3-4
CSb 80 aac 6/7/8 aad CS 80 aa 6/7/8 aa CS 80 aa 6/7/8 aa CS 80 aa 6/7/8 aa
AllergenOnline 0 15 e/0 0 19 e/0 0 24 e/0 0 16 e/0
ADFS 0 6 4/0/0 0 4 8/4/0 0 7 8/4/0 0 5 4/0/0
Allermatch™ 0 7 3/0/0 0 11 2/1/0 0 9 2/1/0 0 8 3/0/0
SDAP 0 1 0/0/0 0 5 2/1/0 0 2 1/1/0 0 2 0/0/0
a The results are represented as number of similar sequences found in accordance with the speciﬁcations for each parameter analyzed.
b The search was done considering the complete sequence (CS) of each protein isoform. To be relevant the identity should be greater than 50% (Aalberse, 2000).
c To be considered relevant the identity must be greater than 35%, on a window of 80 amino acids (Codex Alimentarius, 2009).
d To be considered relevant identity must be 100%, on sequences of 6, 7 or 8 contiguous amino acids.
e In this database it is not possible to do a search for 6 or 7 contiguous amino acid sequences.
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“CQQLRN” and “QQCRQQ”). Likewise, only two different peptides
were found in the search with seven contiguous amino acids
(“RCCQQLR” and “CCQQLRN”). In addition, the peptides found were
not present in epitopes of any known allergenic protein after
analysis in the ADFS.
The search for N-glycosylation sites indicated the absence of
these consensus sequences in Mo-CBP3 isoforms.
3.4. Mode of action and speciﬁcity
Studies on the mode of action of Mo-CBP3 protein is still little
explored since Mo-CBP3 has just been discovered by our research
team. The protein was shown to be able to cross and damage the
plasma membrane and to inhibit the acidiﬁcation of the medium
induced by glucose in F. solani spores. This suggests its inﬂuence on
proton pump (Hþ-ATPase) present in cell membrane of the fungus
responsible for maintaining intracellular pH and electrochemical
gradient necessary for food absorption (Gifoni et al., 2012).
Regarding protein speciﬁcity, Gifoni et al. (2012) have also
shown that the protein was inactive against the oomycete Pythium
oligandrum, which has greater amount of cellulose in the cell wall
rather than chitin, demonstrating so the speciﬁcity of this protein
to chitin.
3.5. In vitro digestibility
Mo-CBP3 protein showed high resistance to degradation by SGF,
even after 2 h of incubation (Fig. 1A). However, when in contact
with SIF the protein proved to be more susceptible to degradation,
being totally hydrolyzed after 2 h of incubation (Fig. 2A). The pro-
tein was detectable by anti-Mo-CBP3 antibody after SGF treatment
(Fig. 1B), whereas it could not be detected after 1 h in SIF (Fig. 2B).
The digestible protein control, BSA, was completely degraded in the
ﬁrst minutes of incubation in both ﬂuids (data not shown).
4. Discussion
Genetic engineering techniques together with conventional
plant breeding have become the main approach for improving
important agronomic crops. The introduction of exogenous genes
into plant genome through genetic engineering adds speciﬁc
characteristics to these crops (Parrott et al., 2010; Gong; Wang,
2013; Hammond et al., 2013). In order to prevent any adverse ef-
fects on human health and other non-target animals, novel proteins
should be rigorously tested for their food and feed safety. Ideally,
the risk assessment should be performed at an early stage in the
timeline of the development of genetically modiﬁed plant (Rice
et al., 2007).Several guidelines to investigate the safety of candidate proteins
for the development of transgenic crops have been developed by
international organizations. In this context, the antifungal protein
Mo-CBP3 was analyzed for food safety using a two-tiered approach,
based on weight of evidence, proposed by ILSI (Delaney et al.,
2008). This is a more ﬂexible approach which contemplates
different analysis and the results are interpreted holistically.
Moreover, this evaluation is consistent with the recommendations
provided by authorities and international organizations such as
FAO/WHO and OECD (OECD, 1996; FAO/WHO, 2001; Codex
Alimentarius, 2009).
The ﬁrst step in the safety assessment includes a search on the
history of safe use of the candidate protein. According to Constable
et al. (2007), the history of safe use of traditional foods constitutes
the reference point for the comparative safety assessment of novel
foods and foods derived from GMO. In the case of proteins derived
from plants, the latter becomes the source of comparison. Impor-
tant factors in establishing a history of safe use include the expo-
sure time of humans or animals to the food, the way the food was
processed and its expected levels of ingestion, potential hazard
associated with consumption and reports of animal and human
exposure and its consequences. Regarding M. oleifera species, its
leaves, pods, seeds and roots have historically been used as food by
humans and animals in many parts of the world with no reports of
adverse effects (Fahey, 2005; Thurber and Fahey, 2009). Another
factor that reduces the risk associated with the ingestion of this
species is its millennial use in traditional medicine and its incor-
poration in herbal formulations (Mehta et al., 2003; Goyal et al.,
2007; Mbikay, 2012). Allied to that, its seeds (the source of Mo-
CBP3 protein) have been successfully used in developing countries
as a natural coagulant in water treatment for human consumption
(Katayon et al., 2006; Vieira et al., 2010; Mangale et al., 2012).
Likewise, the scientiﬁc literature has accumulated a reasonable
certainty about the safe use ofM. oleifera preparations based on the
results of human, animal and in vitro studies (Stohs and Hartman,
2015). As similarly described for other beneﬁcial medicinal/food
plant species, puriﬁed substances and extracts of different parts of
M. oleifera were capable to cause some adverse effects detected by
animal and in vitro tests (previously cited in the Results section). In
general, the popular and scientiﬁc knowledge have pointed out for
no or low toxic effects related to the ingestion of M. oleifera parts.
However, further toxicological studies would be required to better
clarify the synergistic effect of different constituents and their
mode of action.
Another important aspect in the food safety assessment of a
novel protein consists in comparing its primary amino acid
sequence with allergenic, toxic and/or antinutritional proteins. As
there is no recognized deﬁnition of a toxic and/or anti-nutritional
protein based on its primary sequence, the comparison should be
Table 2
Identiﬁed hits (>35% identity) for Mo-CBP3 isoforms in four allergen databases using as search parameter a window of 80 amino acids.
Mo-CBP3 isoforms Identiﬁed hit
Accession number Description/Species Identity (%) E-value Database
Mo-CBP3-1 P80208 Napin 3/Brassica napus 45.03 4.4e-005 AllergenOnline
35.20 9.2e-5 ADFS
46.25 3.4e-07 Allermatch™
P15322 Allergen Sin a 1/Sinapis alba 43.40 6.1e-008 AllergenOnline
36.10 1.1e-7 ADFS
40.24 1.4e-05 Allermatch™
35.19 -a SDAP
AAK15088 Albumin 2S/Sesamum indicum 42.50 1.5e-008 AllergenOnline
CAA62911.1 Allergen Sin a 1.0106/Sinapis alba 41.90 2.6e-007 AllergenOnline
CAA62910.1 Allergen Sin a 1.0105/Sinapis alba 41.20 3.4e-007 AllergenOnline
ACI41244.1 Albumin 2S/Sesamum indicum 41.20 3.4e-005 AllergenOnline
CAA62912.1 Allergen Sin a 1.0107/Sinapis alba 41.20 2.2e-007 AllergenOnline
CAA62909.1 Allergen Sin a 1.0104/Sinapis alba 41.20 9.3e-008 AllergenOnline
CAA62908.1 Allergen Sin a 1.0108/Sinapis alba 40.70 3.7e-007 AllergenOnline
P80207 Allergen Bra j 1-E/Brassica juncea 39.00 0.0058 AllergenOnline
39.02 0.00014 Allermatch™
P04403 2S Albumin Ber e 1/Bertholletia excelsa 37.54 0.0004 AllergenOnline
41.30 1.7e-4 ADFS
2LVF 2S Albumin Ber e 1 - Chain A/Bertholletia excelsa 37.54 0.00028 AllergenOnline
P01089 2S albumin - Allergen Ric c 1/3/Ricinus communis 36.20 1.3 AllergenOnline
Q7Y1C2 2S albumin seed storage protein/Juglans nigra 36.20 0.007 AllergenOnline
35.00 0.00027 Allermatch™
Q9AUD1 2S Albumin - Allergen Ses i 1/Sesamum indicum 41.00 2.4e-5 ADFS
42.50 1e-07 Allermatch™
B6EBI1 2S Albumin - Allergen Ses i ?/Sesamum indicum 40.20 5.9e-5 ADFS
Q8GT96 Recombinant Ib pronapin/Brassica napus 36.10 e AllergenOnline
36.90 6.7e-4 ADFS
Q42473 2S storage protein - Allergen Bra r 1/Brassica rapa 38.75 2.5e-10 Allermatch™
D0PWG2 2S albumin - Allergen Cor a 14/Corylus avellana 35.00 0.00011 Allermatch™
Mo-CBP3-2 AAK15088 Albumin 2S/Sesamum indicum 42.50 1.6e-005 AllergenOnline
40.31 e SDAP
CAA62911.1 Allergen Sin a 1.0106/Sinapis alba 41.40 1.9e-005 AllergenOnline
41.44 e SDAP
P15322 Allergen Sin a 1/Sinapis alba 43.40 1.2e-005 AllergenOnline
36.40 3.1e-5 ADFS
39.02 0.0016 Allermatch™
CAA62910.1 Allergen Sin a 1.0105/Sinapis alba 41.28 5.8e-005 AllergenOnline
CAA62912.1 Allergen Sin a 1.0107/Sinapis alba 41.28 4e-005 AllergenOnline
CAA62909.1 Allergen Sin a 1.0104/Sinapis alba 41.28 1.9e-005 AllergenOnline
40.96 e SDAP
ACI41244.1 Albumin 2S/Sesamum indicum 41.20 3.5e-005 AllergenOnline
P80208 Napin 3/Brassica napus 41.20 0.0037 AllergenOnline
42.50 3.9e-05 Allermatch™
CAA62908.1 Allergen Sin a 1.0108/Sinapis alba 40.20 2.2e-005 AllergenOnline
P01089 2S albumin - Allergen Ric c 1/3/Ricinus communis 38.76 2.4 AllergenOnline
Q8H2B8 2S Albumin - Allergen Ana o 3/Anacardium occidentale 37.50 0.43 AllergenOnline
37.50 0.022 Allermatch™
P80207 Allergen Bra j 1-E/Brassica juncea 37.50 0.078 AllergenOnline
36.59 0.0021 Allermatch™
Q7Y1C2 2S albumin seed storage protein/Juglans nigra 36.20 0.0053 AllergenOnline
37.50 6.4e-05 Allermatch™
D0PWG2 2S albumin - Allergen Cor a 14/Corylus avellana 36.20 0.0019 AllergenOnline
36.25 1.7e-05 Allermatch™
Q8GT96 Recombinant Ib pronapin/Brassica napus 36.20 0.0041 AllergenOnline
35.80 0.0038 ADFS
2LVF 2S Albumin Ber e 1 - Chain A/Bertholletia excelsa 35.02 0.00043 AllergenOnline
P04403 2S Albumin Ber e 1/Bertholletia excelsa 35.02 0.00082 AllergenOnline
35.00 4.5e-06 Allermatch™
36.25 e SDAP
ABG73108.1 2S albumin - Pis v 1 allergen/Pistacia vera 35.01 0.00077 AllergenOnline
Q84XA9 Putative allergen I1/Carya illinoinensis 35.00 0.0046 AllergenOnline
35.00 5.6e-05 Allermatch™
Q9AUD1 2S Albumin - Allergen Ses i 1/Sesamum indicum 40.80 2.9e-5 ADFS
42.50 3.3e-08 Allermatch™
B6EBI1 2S Albumin - Allergen Ses i ?/Sesamum indicum 40.00 2.4e-4 ADFS
Q42473 2S storage protein - Allergen Bra r 1/Brassica rapa 41.25 3.5e-09 Allermatch™
40.83 e SDAP
P93198 Albumin seed storage protein - Jug r 1/Juglans regia 35.00 0.00015 Allermatch™
Mo-CBP3-3 AAK15088 Albumin 2S/Sesamum indicum 41.20 1.6e-007 AllergenOnline
38.00 e SDAP
2LVF 2S Albumin Ber e 1 - Chain A/Bertholletia excelsa 40.20 2e-005 AllergenOnline
P80208 Napin 3/Brassica napus 40.04 0.0011 AllergenOnline
(continued on next page)
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Table 2 (continued )
Mo-CBP3 isoforms Identiﬁed hit
Accession number Description/Species Identity (%) E-value Database
40.00 8.1e-06 Allermatch™
ACI41244.1 Albumin 2S/Sesamum indicum 40.00 3.6e-007 AllergenOnline
P04403 2S Albumin Ber e 1/Bertholletia excelsa 40.00 4e-005 AllergenOnline
35.00 6.4e-6 ADFS
37.50 3.7e-07 Allermatch™
CAA62911.1 Allergen Sin a 1.0106/Sinapis alba 39.10 0.00011 AllergenOnline
42.50 e SDAP
P15322 Allergen Sin a 1/Sinapis alba 39.10 0.00017 AllergenOnline
35.70 1.9e-4 ADFS
40.00 0.0041 Allermatch™
D0PWG2 2S albumin - Allergen Cor a 14/Corylus avellana 38.80 0.00088 AllergenOnline
35.40 3.4e-4 ADFS
38.75 8.1e-06 Allermatch™
CAA62910.1 Allergen Sin a 1.0105/Sinapis alba 38.60 0.00029 AllergenOnline
CAA62912.1 Allergen Sin a 1.0107/Sinapis alba 38.40 0.00025 AllergenOnline
CAA62909.1 Allergen Sin a 1.0104/Sinapis alba 38.40 0.00027 AllergenOnline
CAA62908.1 Allergen Sin a 1.0108/Sinapis alba 37.90 0.00015 AllergenOnline
Q7Y1C2 2S albumin seed storage protein/Juglans nigra 36.24 0.0078 AllergenOnline
36.25 0.00014 Allermatch™
P80207 Allergen Bra j 1-E/Brassica juncea 36.24 0.069 AllergenOnline
36.25 0.0016 Allermatch™
Q8H2B8 2S Albumin - Allergen Ana o 3/Anacardium occidentale 36.21 0.17 AllergenOnline
36.25 0.0069 Allermatch™
AAA34275.1 alpha-type gliadin precursor protein/Triticum aestivum 35.40 3.6 AllergenOnline
P01089 2S albumin - Allergen Ric c 1/3/Ricinus communis 35.30 e AllergenOnline
35.30 1.4e-4 ADFS
Q8GT96 Recombinant Ib pronapin/Brassica napus 35.30 e AllergenOnline
35.30 0.0014 ADFS
CAR82265.1 D-type LMW glutenin subunit, partial/Triticum aestivum 35.04 88 AllergenOnline
CAA25593 unnamed protein product/Triticum aestivum 35.03 5.5 AllergenOnline
AAA17741.1 alpha-gliadin/Triticum aestivum 35.03 4.7 AllergenOnline
BAA12318.1 alpha-gliadin, partial/Triticum aestivum 35.03 1.9eþ002 AllergenOnline
AAA34280.1 alpha/beta-gliadin precursor/Triticum aestivum 35.03 5 AllergenOnline
CAA26384.1 unnamed protein product/Triticum aestivum 35.03 5 AllergenOnline
Q9AUD1 2S Albumin - Allergen Ses i 1/Sesamum indicum 40.20 1.2e-7 ADFS
41.25 1.3e-10 Allermatch™
B6EBI1 2S Albumin - Allergen Ses i ?/Sesamum indicum 39.03 2.7e-7 ADFS
Q42473 2S storage protein - Allergen Bra r 1/Brassica rapa 41.25 3.5e-09 Allermatch™
Mo-CBP3-4 P15322 Allergen Sin a 1/Sinapis alba 44.60 9.7e-008 AllergenOnline
36.80 7.3e-8 ADFS
40.24 6.6e-05 Allermatch™
37.15 e SDAP
P80208 Napin 3/Brassica napus 43.75 0.00018 AllergenOnline
45.00 4.4e-06 Allermatch™
CAA62911.1 Allergen Sin a 1.0106/Sinapis alba 43.00 3.9e-007 AllergenOnline
CAA62910.1 Allergen Sin a 1.0105/Sinapis alba 42.50 5e-007 AllergenOnline
CAA62912.1 Allergen Sin a 1.0107/Sinapis alba 42.50 3.3e-007 AllergenOnline
CAA62909.1 Allergen Sin a 1.0104/Sinapis alba 42.50 1.5e-007 AllergenOnline
CAA62908.1 Allergen Sin a 1.0108/Sinapis alba 41.90 5.4e-007 AllergenOnline
AAK15088 Albumin 2S/Sesamum indicum 41.20 4.1e-005 AllergenOnline
40.00 e SDAP
ACI41244.1 Albumin 2S/Sesamum indicum 40.00 9.4e-005 AllergenOnline
2LVF 2S Albumin Ber e 1 - Chain A/Bertholletia excelsa 38,71 0.00026 AllergenOnline
P04403 2S Albumin Ber e 1/Bertholletia excelsa 38.71 0.00037 AllergenOnline
42.90 8.6e-5 ADFS
P80207 Allergen Bra j 1-E/Brassica juncea 37.80 0.011 AllergenOnline
37.80 0.00055 Allermatch™
D0PWG2 2S albumin - Allergen Cor a 14/Corylus avellana 36.24 0.0033 AllergenOnline
36.25 0.00017 Allermatch™
P01089 2S albumin - Allergen Ric c 1/3/Ricinus communis 36.20 1.7 AllergenOnline
Q7Y1C2 2S albumin seed storage protein/Juglans nigra 36.20 0.0078 AllergenOnline
36.25 0.00048 Allermatch™
Q8GT96 Recombinant Ib pronapin/Brassica napus 35.20 e AllergenOnline
35.20 5.3e-4 ADFS
Q9AUD1 2S Albumin - Allergen Ses i 1/Sesamum indicum 40.20 3.3e-5 ADFS
41.25 9.8e-07 Allermatch™
B6EBI1 2S Albumin - Allergen Ses i ?/Sesamum indicum 39.30 8.1e-5 ADFS
Q42473 2S storage protein - Allergen Bra r 1/Brassica rapa 38.75 8.7e-10 Allermatch™
P93198 Albumin seed storage protein - Jug r 1/Juglans regia 35.00 0.00086 Allermatch™
a Not provided.
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Fig. 1. SDS-PAGE (17.5%) (A) and Western Blot (B) proﬁles of Mo-CBP3 (<14.4 kDa) at a concentration of 0.5 mg/mL in SGF digestion. M: molecular mass markers (phosphorylase
Be97 kDa; bovine serum albumine66 kDa; ovalbumine45 kDa; carbonic anhydrasee29 kDa; soybean trypsin inhibitore20.1 kDa and lactalbumin 14.4 kDa); SGF: SGF without
incubation; SGF0: SGF with incubation for 2 h.
Fig. 2. SDS-PAGE (17.5%) (A) and Western Blot (B) proﬁles of Mo-CBP3 (<14.4 kDa) at a concentration of 0.5 mg/mL in SIF digestion. M: molecular mass markers (phosphorylase
Be97 kDa; bovine serum albumine66 kDa; ovalbumine45 kDa; carbonic anhydrasee29 kDa; soybean trypsin inhibitore20.1 kDa and lactalbumin 14.4 kDa); SIF: SIF without
incubation; SIF0: SIF with incubation for 2 h.
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conservative approach. The identiﬁed proteins with signiﬁcant
identity using a local alignment algorithm are then evaluated for
their relevance in causing adverse effects (Codex Alimentarius,
2009; Madduri et al., 2012). Mo-CBP3 protein showed no identity
with any allergenic, toxic and/or antinutritional protein sequences
deposited in seven large databases.
The allergenic potential of a protein can be assessed by
comparing its primary amino acid sequence with those of known
allergens (FAO/WHO, 2001; Ladics, 2008; Codex Alimentarius,
2009; Cressman and Ladics, 2009; Ladics et al., 2011). Compari-
son of the full-length sequences of the four Mo-CBP3 isoforms in
ADFS, Allermatch™, AllergenOnline and SDAP allergen databases
showed no similarity with any known allergenic proteins. Accord-
ing to Aalberse (2000), alignments with high identity scores may
indicate a potential for allergenic cross-reactions. Cross-reactivity is
not likely for proteins with less than 50% identity over the entire
protein sequence and it is fairly common above 70% identity.
As recommended by Codex Alimentarius (2009), the possi-
bility of a cross-reaction between a novel protein and a known
allergen is considered when the identity between them is >35%
on a window of 80 amino acids. Proteins sharing high identity by
local alignment programs, such as FASTA or BLASTP, are highly
likely to cause cross-reactions (Goodman et al., 2005, 2008).
Hence, they must be subjected to in vitro experiments with sera
from atopic patients (allergic) to evaluate their potential in trig-
gering allergic reactions (Thomas et al., 2009; Randhawa et al.,
2011). According to this criterion, Mo-CBP3 isoforms showed
identity with several known allergens. Among them, stand out 2S
albumins from several plant species such as B. excelsa, Brassica
napus, C. avellana, Sesamum indicum, and Si. alba. Thus, this result
provides sufﬁcient evidences to indicate that Mo-CBP3 proteinmust be submitted to further hypothesis-based testing on its
potential allergenicity.
The allergenic potential of proteins is also evaluated through
research with small segments of identical contiguous amino acids.
FAO/WHO (2001) recommends searches of six to eight contiguous
amino acids. The research by using six and seven contiguous amino
acids revealed identity of known allergens withMo-CBP3 isoforms.
However, with the criterion of eight contiguous amino acids no
identity could be observed. The approach using six contiguous
amino acids is often criticized for generating high rate of false
positives (K€onig et al., 2004). Many random results that show no
risk of cross-reaction is observed when a short sequence of amino
acids is used (Hileman et al., 2002). A research with eight contig-
uous amino acids is probably more effective in detection of
immunogenic epitopes (ILSI HESI, 2001; Hileman et al., 2002). In
addition, the peptides found for Mo-CBP3 were not present in any
known allergenic protein epitopes. For the allergic response to be
triggered, at least two IgE-binding epitopes on the same protein are
required (Huby et al., 2000; Ladics, 2008).
Many allergens are glycosylated proteins, raising the possibility
that the glycosyl groups may contribute to its allergenicity (Jenkins
et al., 1996). Mo-CBP3 did not present potential N-glycosylation
sites by in silico sequence analysis. On the other hand, sites of O-
glycosylation inMo-CBP3 have been detected (Freire et al., 2015). In
addition, experimental results revealed that Mo-CBP3 is a glyco-
protein with 2.5% carbohydrate in its structure (Gifoni et al., 2012).
However, the current knowledge about the structures and possible
epitopes of oligosaccharides linked to allergenic glycoproteins
show thatN-glycans aremore often involved in the structures of IgE
epitopes (F€otisch and Vieths, 2001; Altmann, 2007).
It is known that the antifungal properties of Mo-CBP3 are trig-
gered by alterations in the cell surface (Gifoni et al., 2012). In fact,
C.E.M. Pinto et al. / Food and Chemical Toxicology 83 (2015) 1e98Mo-CBP3 was able to permeabilize the plasma membrane (using
propidium iodide as probe) of F. solani spores. Moreover, this pro-
tein appeared to interfere directly or indirectly with the plasma
membrane Hþ-ATPase pump. Similar mode of action has also been
demonstrated by other antifungal proteins like soybean toxin
(SBTX) (Morais et al., 2010) and PvD1 of Phaseolus vulgaris (Mello
et al., 2011). The proton pump present in the fungal membrane is
responsible for maintenance of intracellular pH and electro-
chemical gradient which are required for absorption of food (Monk
and Perlin, 1994). Disruption of plasma membrane caused by Mo-
CBP3 can affect the function of this proton-translocating ATPase
enzyme and the trafﬁc of substances across the membrane, which
could lead to cell death, as suggested for other plant proteins (Ben-
Josef et al., 2000; Mello et al., 2011). It is noteworthy that the
presence of chitin in the fungi cell wall is crucial forMo-CBP3 action,
which confers a margin of safety for mammals. The mechanism of
action and speciﬁcity of Mo-CBP3 is a target of intense studies by
our group and soon more details about this topic can be revealed.
With few exceptions, all allergenic proteins have high stability
to digestive enzymes. Thus, this stability is used as an indicator of
the allergenic potential of a protein (Astwood and Fuchs,1996).Mo-
CBP3 showed to be highly resistant to degradation by SGF, even
after 2 h of incubation, but was susceptible to SIF. Therefore, Mo-
CBP3 could be a concern related to trigger an allergenic response,
especially when this result is grouped with the ﬁndings of the in
silico search on awindow of 80 amino acids. In addition, it has been
recently reported that Mo-CBP3 is highly stable at temperatures
(100 C) and pH extremes for up to 1 h, maintaining its three-
dimensional structure and antifungal activity almost unchanged
(Batista et al., 2014). Thermal stability has been associated with the
allergenic potential of many proteins. This feature comes to rein-
force the concerns about the allergenic potential of Mo-CBP3.
The set of tests that comprises the Tier I from the two-tiered
approach proposed by ILSI for risk assessment of novel proteins
gathered weight of evidence that Mo-CBP3 possesses a potential to
trigger allergies. Thus, a Tier II composed by a guided study with
sera of allergic patients must be conducted in order to conﬁrm this
hypothesis.5. Conclusions
The obtained results contributed to gather a relevant dataset on
food safety of the Mo-CBP3, an antifungal protein isolated from
M. oleifera seeds. Many positive attributes were presented for this
protein. However, Mo-CBP3 showed high sequence homology with
allergens that indicates that further hypothesis-based testing on its
potential allergenicity must be done before its use for plant trans-
formation. Additionally, animal toxicity evaluations (e.g. acute and
repeated dose oral exposure assays) must be performed tomeet the
mandatory requirements of several regulatory agencies. Finally, the
approach adopted here exempliﬁed the importance of performing
an early risk assessment of candidate proteins for use in plant
transformation programs. This may avoid huge economic and time
consuming efforts, as well as may help to guidemodiﬁcations in the
protein structure in order to free it of its potential risks.Acknowledgments
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